Is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. Research and Development Programs.
http://www.decimmune.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Thursday
LOAD TIME
1 seconds
Natural Antibodies
Natural Antibodies
800 Hun●●●●●●● Avenue
Bo●●on , MA, 02115
UNITED STATES
View this contact
Natural Antibodies
Richard Foemmel
800 Hun●●●●●●● Avenue
Bo●●on , MA, 02115
UNITED STATES
View this contact
Verio
Verio Hostmaster
5050 B●●●●●●ke Dr.
Boc●●●ton , FL, 33431
UNITED STATES
View this contact
BUY YOUR DOMAIN
19
YEARS
11
MONTHS
15
DAYS
MELBOURNE IT, LTD. D/B/A INTERNET NAMES WORLDWIDE
WHOIS : whois.melbourneit.com
REFERRED : http://www.melbourneit.com
PAGES IN
THIS WEBSITE
6
SSL
EXTERNAL LINKS
5
SITE IP
66.96.146.129
LOAD TIME
0.997 sec
SCORE
6.2
DecImmune Therapeutics : Home Page | decimmune.com Reviews
https://decimmune.com
Is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. Research and Development Programs.
decimmune.com
DecImmune Therapeutics : News : Press Releases
http://www.decimmune.com/news.html
October 3, 2014. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. April 22, 2013. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. February 26, 2013. DecImmune Therapeutics Secures $2.25 Million in Development Funding. September 27, 2010. DecImmune Therapeutics Secures $3.2 Million in Development Funding. Research and Development Programs.
DecImmune Therapeutics : Sitemap
http://www.decimmune.com/sitemap.html
Research and Development Programs. Research and Development Programs.
DecImmune Therapeutics : About : Overview
http://www.decimmune.com/about.html
Michael Carroll, PhD. Francis Moore, MD. Christopher K. Mirabelli, PhD. Walter Newman, PhD. Amgen Ventures, Astellas Venture Management and Broadview Ventures, in addition to $7 million in NIH SBIR grant funding. Research and Development Programs.
DecImmune Therapeutics : Home Page
http://www.decimmune.com/index.html
Is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. Research and Development Programs.
DecImmune Therapeutics : Science
http://www.decimmune.com/science.html
N2 Pathway: Critical to Autoimmunity. The N2 pathway is central to innate autoimmune inflammatory processes. Multiple stressors can induce expression of the N2 epitope of non-muscle myosin heavy chain within large and small vessels. Now N2 gains access to circulating pathogenic IgM and activation of a downstream cascade of inflammation and tissue damage ensues. N2-Driven Inflammatory Cascade Inhibited by DeciMab. We have developed a humanized antibody, DeciMab, that blocks the N2 cascade.
TOTAL PAGES IN THIS WEBSITE
6
Boston Children's Hospital's Startup Companies | Boston Children's Hospital TIDO
http://www.childrensinnovations.org/Pages/ForIndustry/bdFAQs.aspx
Apply for Tech Dev Funds. Sign up for Newsletter. Licensing Managers by Dept. MTAs, CDAs and Consulting. Proof of Concept Grant. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Patents and Licensing Group. Licensing Managers by Dept. Business Development and Marketing Group. Business and Administration Group. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Business Development and Partnering.
Boston Children's Hospital's Startup Companies | Boston Children's Hospital TIDO
http://www.childrensinnovations.org/Pages/Highlights/StartUps.aspx
Apply for Tech Dev Funds. Sign up for Newsletter. Licensing Managers by Dept. MTAs, CDAs and Consulting. Proof of Concept Grant. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Patents and Licensing Group. Licensing Managers by Dept. Business Development and Marketing Group. Business and Administration Group. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Business Development and Partnering.
Boston Children's Hospital's Startup Companies | Boston Children's Hospital TIDO
http://www.childrensinnovations.com/Pages/Highlights/StartUps.aspx
Apply for Tech Dev Funds. Sign up for Newsletter. Licensing Managers by Dept. MTAs, CDAs and Consulting. Proof of Concept Grant. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Patents and Licensing Group. Licensing Managers by Dept. Business Development and Marketing Group. Business and Administration Group. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Business Development and Partnering.
Boston Children's Hospital's Startup Companies | Boston Children's Hospital TIDO
http://www.childrensinnovations.org/Pages/PatentsAndLicensing/Policies.aspx
Apply for Tech Dev Funds. Sign up for Newsletter. Licensing Managers by Dept. MTAs, CDAs and Consulting. Proof of Concept Grant. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Patents and Licensing Group. Licensing Managers by Dept. Business Development and Marketing Group. Business and Administration Group. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Business Development and Partnering.
Technology Newsletter | Boston Children's Hospital TIDO
http://www.childrensinnovations.com/Pages/General/NewsletterAlerts.aspx
Apply for Tech Dev Funds. Sign up for Newsletter. Licensing Managers by Dept. MTAs, CDAs and Consulting. Proof of Concept Grant. Licensed Products in Clinical Trials. Licensed Products on the Market. News and Press Releases. Patents and Licensing Group. Licensing Managers by Dept. Business Development and Marketing Group. Business and Administration Group. Boston Children's Hospital's Startup Companies. Rarr; Booz Allen Hamilton. CoStim Pharmaceuticals → Novartis. Premacure → Shire.
TOTAL LINKS TO THIS WEBSITE
5
LUCES DE MI SER EN FLOR
LUCES DE MI SER EN FLOR. Martes, 21 de octubre de 2008. EL MAÑANA QUE SE ESPERA. El ayer su luz confía. 161;NO HAY DESARROLLO SOCIAL! Si en el orbe hay corrupción. Y es notorio el desempleo. Se pone el ambiente feo. Por andar sin proyección. Si no hay buena educación. Al crecimiento no hay vía. Que hasta en la fuerza bravía. No hay su esencia de verdad,. De esa dura realidad. EL AYER SU LUZ CONFÍA. Si hay la crisis de valores. Se vuelve todo falacia. Junto a crueles sinsabores. Y el horizonte vital.
decimistasurbanos.blogspot.com
DECIMISTAS URBANOS
Viernes, 11 de junio de 2010. Http:/ www.deciman.blogspot.com/. Http:/ www.elcolorao.com/. Http:/ www.ensamble12.com.ve/. Http:/ manualidadesrocio.blogspot.com/. Http:/ www.juanperezproducciones.com/. Http:/ cantoladecima.blogspot.com/. Http:/ josegranadodecimas.blogspot.com/. Http:/ www.peglez.blogspot.com. Miércoles, 9 de junio de 2010. Esta página está en construcción. Suscribirse a: Entradas (Atom). Bienvenidosesta página está en construcción. Ver todo mi perfil.
Decimix - DeviantArt
Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')" class="mi". Window.devicePixelRatio*screen.width 'x' window.devicePixelRatio*screen.height) :(screen.width 'x' screen.height) ; this.removeAttribute('onclick')". Join DeviantArt for FREE. Forgot Password or Username? Deviant for 3 Years. This deviant's full pageview. Last Visit: 18 weeks ago. This is the place where you can personalize your profile! 8226; Lo...
deciml.com - Registered at Namecheap.com
This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! This domain is registered at Namecheap. This domain was recently registered at Namecheap. Please check back later! The Sponsored Listings displayed above are served automatically by a third party. Neither Parkingcrew nor the domain owner maintain any relationship with the advertisers.
www.decimmo.com
This Web page parked FREE courtesy of Temecula Valley Domain Registrar. Search for domains similar to. Is this your domain? Let's turn it into a website! Would you like to buy this. Find Your Own Domain Name. See our full line of products. Easily Build Your Professional Website. As low as $4.25/mo. Call us any time day or night (480) 624-2500.
DecImmune Therapeutics : Home Page
Is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. Research and Development Programs.
DecImmune Therapeutics : Home Page
Is developing a novel monoclonal antibody, DeciMab™, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. DecImmune Therapeutics Awarded $3 Million in SBIR Phase IIB Funding. DSM and DecImmune Sign Agreement to Develop N2 Pathway Blocking Antibody. Research and Development Programs.
Um percurso em construção
Um percurso em construção. Sexta-feira, novembro 19. Barack Obama aterrou hoje em Portugal por volta das 10h e 57 minutos. Segundo o Correio da Manhã, o primeiro-ministro José Sócrates recebeu o presidente dos Estados Unidos à porta da sua residência oficial em S. Bento. O primeiro-ministro, José Sócrates, e o presidente dos Estados Unidos, Barack Obama, debatem as relações económicas bilaterais, com destaque para as energias renováveis e a crise internacional financeira, e o processo de reforma da NATO.
Decimo Arte El Mundo del Baile
Html, body { height:100%; background-color: #000000;} body { margin:0; padding:0; overflow:hidden; background-image: url(fondo2.jpg); background-color: #666; background-repeat: repeat; } #flashContent { width:100%; height:100%; } body,td,th { color: #FFF; } a:visited { color: #F0F; } Bienvenido Saltar Intro VERSION MOVIL Academia de Baile o Saltar Intro VERSION MOVIL Academia de Baile .
EDUCACIÓN AL RECICLADO Y A LA REUTILIZACIÒN
EDUCACIÓN AL RECICLADO Y A LA REUTILIZACIÒN. Viernes, 2 de septiembre de 2011. El Reciclado de Plásticos. La reducción en la fuente se refiere directamente al diseño y a la etapa productiva de los productos, principalmente envases, antes de ser consumidos. Etapas para reciclar el plástico:. El reciclado mecánico es un proceso físico mediante el cual el plástico post-consumo o el industrial (. Es recuperado, permitiendo su posterior utilización. Estos se dividen a su vez en tres clases:. Se añaden burbuja...
Blog de Decimo-X - Blog de Ooo-J-4a-m3l-ooO - Skyrock.com
Mot de passe :. J'ai oublié mon mot de passe. Plus d'actions ▼. S'abonner à mon blog. 9829; A Toi. (Le Prince). Je m'ennuie :(. Mercredi 01 juillet 2015 05:46. Création : 22/02/2009 à 14:12. Mise à jour : 31/07/2015 à 08:47. Je suis fatigué patron, fatigué de devoir courir les routes et d'être seul comme un moineau sous la pluie. Fatigué d'avoir jamais un ami pour parler, pour me dire où on va, d'où on vient et pourquoi. Tu ne peux pas voir le blog de Decimo-X car vous n'êtes pas amis. Poster sur mon blog.
